Qiu Y, Man C, Zhu L, Zhang S, Wang X, Gong D
Mol Cancer. 2024; 23(1):232.
PMID: 39425197
PMC: 11487993.
DOI: 10.1186/s12943-024-02148-y.
Hwang W, Park K, Park S, Cheon N, Lee J, Hwang T
Leukemia. 2024; 38(6):1353-1364.
PMID: 38514771
PMC: 11147762.
DOI: 10.1038/s41375-024-02228-4.
Winstone L, Jung Y, Wu Y
Biochem Soc Trans. 2024; 52(1):395-405.
PMID: 38348889
PMC: 10903454.
DOI: 10.1042/BST20230725.
Zoller J, Trajanova D, Feurstein S
Front Oncol. 2023; 13:1205855.
PMID: 37904876
PMC: 10613526.
DOI: 10.3389/fonc.2023.1205855.
Qiu H, Qiao C, Yang H, Guo R, Shi Y, Zhao X
Zhonghua Xue Ye Xue Za Zhi. 2023; 44(8):676-679.
PMID: 37803843
PMC: 10520237.
DOI: 10.3760/cma.j.issn.0253-2727.2023.08.011.
DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation.
Rolles B, Meyer R, Begemann M, Elbracht M, Jost E, Stelljes M
Blood Cancer J. 2023; 13(1):73.
PMID: 37160870
PMC: 10170132.
DOI: 10.1038/s41408-023-00846-2.
Ribosome profiling analysis reveals the roles of DDX41 in translational regulation.
Tungalag S, Shinriki S, Hirayama M, Nagamachi A, Kanai A, Inaba T
Int J Hematol. 2023; 117(6):876-888.
PMID: 36780110
DOI: 10.1007/s12185-023-03558-2.
Current Understanding of Mutations in Myeloid Neoplasms.
Kim K, Ong F, Sasaki K
Cancers (Basel). 2023; 15(2).
PMID: 36672294
PMC: 9857085.
DOI: 10.3390/cancers15020344.
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J
Blood. 2022; 141(5):534-549.
PMID: 36322930
PMC: 10935555.
DOI: 10.1182/blood.2022018221.
Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis.
Shinriki S, Matsui H
Front Oncol. 2022; 12:992340.
PMID: 36119490
PMC: 9478608.
DOI: 10.3389/fonc.2022.992340.
Clinical and mechanistic insights into the roles of DDX41 in haematological malignancies.
Weinreb J, Bowman T
FEBS Lett. 2022; 596(21):2736-2745.
PMID: 36036093
PMC: 9669125.
DOI: 10.1002/1873-3468.14487.
The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.
Li P, Brown S, Williams M, White T, Xie W, Cui W
Blood. 2022; 140(7):716-755.
PMID: 35671390
PMC: 9389629.
DOI: 10.1182/blood.2021015135.
DDX41 is required for cGAS-STING activation against DNA virus infection.
Singh R, Vidhyasagar V, Yang S, Arna A, Yadav M, Aggarwal A
Cell Rep. 2022; 39(8):110856.
PMID: 35613581
PMC: 9205463.
DOI: 10.1016/j.celrep.2022.110856.
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.
Duployez N, Largeaud L, Duchmann M, Kim R, Rieunier J, Lambert J
Blood. 2022; 140(7):756-768.
PMID: 35443031
PMC: 9389637.
DOI: 10.1182/blood.2021015328.
DEAD-Box RNA Helicases and Genome Stability.
Cargill M, Venkataraman R, Lee S
Genes (Basel). 2021; 12(10).
PMID: 34680866
PMC: 8535883.
DOI: 10.3390/genes12101471.
AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome.
Li P, White T, Xie W, Cui W, Peker D, Zeng G
Leukemia. 2021; 36(3):664-674.
PMID: 34671111
DOI: 10.1038/s41375-021-01404-0.
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.
Yang F, Long N, Anekpuritanang T, Bottomly D, Savage J, Lee T
Blood. 2021; 139(8):1208-1221.
PMID: 34482403
PMC: 9211447.
DOI: 10.1182/blood.2021011354.
Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia.
Chlon T, Stepanchick E, Hershberger C, Daniels N, Hueneman K, Davis A
Cell Stem Cell. 2021; 28(11):1966-1981.e6.
PMID: 34473945
PMC: 8571055.
DOI: 10.1016/j.stem.2021.08.004.
Clinical features of mutation-related diseases: a systematic review with individual patient data.
Wan Z, Han B
Ther Adv Hematol. 2021; 12:20406207211032433.
PMID: 34349893
PMC: 8287267.
DOI: 10.1177/20406207211032433.
Genetics of Myelodysplastic Syndromes.
Saygin C, Godley L
Cancers (Basel). 2021; 13(14).
PMID: 34298596
PMC: 8304604.
DOI: 10.3390/cancers13143380.